Soluble tumor necrosis factor-alpha receptor type 1 during selenium supplementation in psoriasis patients (Q44618005)

4 December 2017

Soluble tumor necrosis factor-alpha receptor type 1 during selenium supplementation in psoriasis patients (English)

1 reference

4 December 2017

Hanna Mysliwiec

2

0 references

Agnieszka B Serwin

object named as

Agnieszka B Serwin

1

0 references

Maria H Borawska

object named as

Maria Borawska

5

0 references

author name string

Katarzyna Hukalowicz

3

1 reference

PubMed ID

14559319

4 December 2017

Piotr Porebski

4

1 reference

PubMed ID

14559319

4 December 2017

Bozena Chodynicka

6

1 reference

4 December 2017

1 October 2003

1 reference

4 December 2017

1 reference

4 December 2017

19

1 reference

4 December 2017

10

1 reference

4 December 2017

847-850

1 reference

The importance of selenium to human health

4 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2803%2900165-5

7 January 2021

Effect of selenium on the expression of high affinity interleukin 2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2803%2900165-5

7 January 2021

Modulatory effects of selenium and strontium salts on keratinocyte-derived inflammatory cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2803%2900165-5

7 January 2021

The effect of supplementation with selenium and vitamin E in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2803%2900165-5

7 January 2021

Selenium status in psoriasis and its relations to the duration and severity of the disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2803%2900165-5

7 January 2021

Clinical and biological effects of balneotherapy with selenium-rich spa water in patients with psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2803%2900165-5

7 January 2021

Nutritional selenium supplements: product types, quality, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2803%2900165-5

7 January 2021

Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2803%2900165-5

7 January 2021

An important role of tumor necrosis factor-alpha in the induction of adhesion molecules in psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2803%2900165-5

7 January 2021

Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2803%2900165-5

7 January 2021

Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2803%2900165-5

7 January 2021

Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2803%2900165-5

7 January 2021

The effect of treatment on serum levels of soluble intercellular adhesion molecules and tumour necrosis factor-receptor 1 in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2803%2900165-5

7 January 2021

Severe Psoriasis – Oral Therapy with a New Retinoid

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2803%2900165-5

7 January 2021

Soluble E-selectin and soluble tumour necrosis factor receptor (60 kD) serum levels in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2803%2900165-5

7 January 2021

10.1016/S0899-9007(03)00165-5

Identifiers

DOI

1 reference

4 December 2017

1 reference

PubMed ID

14559319